Joel H. Kaufman
2018
In 2018, Joel H. Kaufman earned a total compensation of $313.4K as Chief Business Officer at Navidea Biopharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $78,751 |
|---|---|
| Option Awards | $5,176 |
| Salary | $225,000 |
| Other | $4,493 |
| Total | $313,420 |
Kaufman received $225K in salary, accounting for 72% of the total pay in 2018.
Kaufman also received $78.8K in non-equity incentive plan, $5.2K in option awards and $4.5K in other compensation.
Rankings
In 2018, Joel H. Kaufman's compensation ranked 13,070th out of 14,244 executives tracked by ExecPay. In other words, Kaufman earned more than 8.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 13,070 out of 14,244 | 8th |
Division Manufacturing | 5,288 out of 5,758 | 8th |
Major group Chemicals And Allied Products | 1,974 out of 2,119 | 7th |
Industry group Drugs | 1,693 out of 1,808 | 6th |
Industry In Vitro and In Vivo Diagnostic Substances | 62 out of 72 | 14th |
Source: SEC filing on August 2, 2021.
Kaufman's colleagues
We found four more compensation records of executives who worked with Joel H. Kaufman at Navidea Biopharmaceuticals in 2018.
News
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019